Compare AISP & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AISP | ELOX |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 60.3M |
| IPO Year | 2021 | 2013 |
| Metric | AISP | ELOX |
|---|---|---|
| Price | $2.23 | $15.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.25 |
| AVG Volume (30 Days) | ★ 191.9K | 21.4K |
| Earning Date | 11-16-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.48 | 41.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $15,321,349.00 | N/A |
| Revenue This Year | $78.84 | N/A |
| Revenue Next Year | $47.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.69 | $10.00 |
| 52 Week High | $7.20 | $23.40 |
| Indicator | AISP | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 44.16 |
| Support Level | $1.94 | $13.92 |
| Resistance Level | $2.11 | $19.43 |
| Average True Range (ATR) | 0.06 | 1.39 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 81.50 | 23.89 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture. Airship AI's software allows customers to view structured data both in real-time as well as to conduct searches on the structured data at a later point in time.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.